D R Khasanova

Plain English
This research paper looks at how a treatment called Cerebrolysin can improve outcomes for patients suffering from acute ischemic stroke when used alongside standard reperfusion therapy. The study showed that Cerebrolysin not only helps recovery but also protects key brain structures, with the potential for better patient results. Identifying the right patients who would benefit the most from this combined treatment is crucial for maximizing its effectiveness. Who this helps: This helps stroke patients by potentially improving their recovery chances.

Plain English
This study looked at the use of the drug Fortelyzin to treat patients who had an acute ischemic stroke (AIS) when they received treatment between 4.5 and 24 hours after their symptoms started. Researchers found that 61% of patients treated within the first 4.5 hours had a good recovery, while 65% of those treated later also had a good recovery, showing that treatment is still effective even when started later. The rates of serious complications were similar in both groups, indicating that Fortelyzin is a safe option for stroke patients, regardless of when they receive treatment. Who this helps: This helps stroke patients who may not get to the hospital within the first few hours of their symptoms.

Plain English
This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings. Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.

Plain English
This study looked at how a treatment called Cerebrolysin affects the timing of when stroke patients can safely restart their blood-thinning medication after a stroke. The researchers found that Cerebrolysin significantly lowered the risk of dangerous complications called hemorrhagic transformations, reducing the risk of these events by 75% for symptomatic cases and by 46% for any type of hemorrhage within two weeks after the stroke. These findings can help doctors make better decisions about resuming anticoagulation therapy based on a patient's risk level, allowing safer management of their treatment. Who this helps: This helps stroke patients and their doctors.

Plain English
This study looked at how well botulinum therapy (Dysport) worked for people in Russia with cervical dystonia, a condition that causes muscle spasms and abnormal posture in the neck. Over three years, patients' symptom severity scores decreased significantly from an average of 32.3 to 25.2, and satisfaction with treatment improved from 92.5% to 98.1% at peak effectiveness. This is important because it shows that Dysport remains an effective and satisfying treatment option for managing cervical dystonia in real-world settings. Who this helps: This benefits patients with cervical dystonia and their healthcare providers.

Plain English
This research review looks at the drug Dimephosphon and how it can help balance the body's automatic functions, like heart rate and digestion. The studies showed that Dimephosphon works in different ways to improve bodily functions, making it safe and effective for patients. This is important because it offers a new treatment option for conditions related to problems with the autonomic nervous system. Who this helps: This helps patients experiencing issues with their autonomic nervous system.

Plain English
This study looked at how a treatment called Cerebrolysin works when combined with other therapies for patients who have had a stroke caused by a blockage in blood flow. Researchers found that after two weeks, patients who received Cerebrolysin had better brain health measures, with higher indicators of brain microstructure integrity and a smaller area of brain damage compared to those who did not receive it. Specifically, these patients showed a 7-mL reduction in brain damage volume and had improved brain imaging results that suggest better overall recovery. Who this helps: This benefits patients who have had an ischemic stroke, offering them a potentially more effective treatment option.

Plain English
This study looked at how new treatments for ischemic stroke (IS) are being used in Russia from 2015 to early 2025. Researchers found that more patients are getting treated quickly after symptoms start, with those admitted within 4.5 hours rising from 23% in 2015 to 31% in 2024. The use of reperfusion treatments, like IVT and thrombectomy, also increased significantly, leading to a reduction in mortality rates from 16.8% in 2015 to 12.6% in 2025. This matters because faster and better treatment can help more people survive strokes and recover their abilities. Who this helps: This helps patients who suffer from strokes and improve outcomes through timely medical interventions.

Plain English
This study examined the effectiveness of a medication called Mexidol for patients recovering from ischemic stroke, comparing it to a placebo. In the trial involving 304 patients, those who received Mexidol showed significant improvements in disability and neurological symptoms, with more patients reporting better mobility and less cognitive impairment than those who received the placebo. Specifically, the Mexidol group had a median improvement on the disability scale compared to the start of treatment, indicating that it helps patients recover better after a stroke. Who this helps: This research benefits patients recovering from ischemic stroke.

Plain English
This study looked at the timing of resuming blood-thinning medication (anticoagulation) after a specific type of stroke, focusing on whether a drug called Cerebrolysin can help reduce the risk of bleeding complications. Researchers analyzed data from 238 patients and found that Cerebrolysin significantly decreased the chances of bleeding issues in high-risk patients from 14.5% to 4.5%, and it allowed for a safer and earlier resumption of anticoagulation. These results could help tailor treatment for stroke patients at risk of bleeding, potentially improving their recovery and safety. Who this helps: This helps patients who have suffered an ischemic stroke and are at high risk of bleeding complications.

Plain English
This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options. Who this helps: Patients with acute ischemic stroke and their healthcare providers.

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

Plain English
This study examined the effects of a drug called Cerebrolysin when given early alongside standard treatment for patients who had an ischemic stroke, which is caused by a blocked blood vessel. Researchers looked at 238 patients with different levels of risk for bleeding in the brain (hemorrhagic transformation). They found that those with moderate to high risk (risk scores of 1 or higher) experienced a notable improvement: the rate of bleeding decreased, and their ability to function improved significantly, while those at low risk showed no benefits. Who this helps: This research benefits stroke patients, especially those at moderate to high risk for complications related to bleeding.

Plain English
This study looked at how to treat and rehabilitate patients who experience neurological problems after having COVID-19. Experts found that many people suffer from issues like memory loss, fatigue, and other brain-related symptoms even years after infection. This is important because it helps us understand the need for tailored care and rehabilitation strategies for these patients to improve their quality of life. Who this helps: Patients recovering from COVID-19 who experience neurological symptoms.

Plain English
This study looked at the effects of adding a drug called Cerebrolysin to the standard treatment for stroke, known as reperfusion therapy, in patients who had a type of stroke caused by a blocked blood vessel. Researchers found that patients who received Cerebrolysin alongside the standard treatment had a 75% lower risk of developing a serious complication known as symptomatic hemorrhagic transformation compared to those who received the standard treatment alone. This is important because it suggests that Cerebrolysin can help reduce the risk of complications and improve early recovery after a stroke. Who this helps: This helps stroke patients by potentially improving their treatment outcomes and reducing complications.

Plain English
This study looked at the use of Fortelyzin in treating patients with acute ischemic strokes by comparing it to another treatment called Actilyse. Researchers found that the average time from when patients arrived at the hospital to when they began treatment was shorter for those taking Fortelyzin, and serious complications (like bleeding in the brain) occurred less frequently at 6% compared to 8% with Actilyse. Overall, 47% of patients treated with Fortelyzin had a positive recovery outcome, slightly higher than the 42% in the Actilyse group, showing that Fortelyzin is a safe and effective option for stroke treatment. Who this helps: This benefits patients suffering from acute ischemic strokes and their healthcare providers.

Plain English
This study looked at whether combining two treatments, Cerebrolysin and Alteplase, helps stroke patients by reducing brain bleeding and improving their recovery. The results showed that among 126 patients given both treatments, the risk of severe bleeding was significantly lower, with an odds ratio of 0.248, meaning they were much less likely to have this issue compared to 215 patients who only received Alteplase. While there was early improvement in neurological function, the long-term functional outcomes were similar for both groups at 90 days. Who this helps: Stroke patients and their doctors.

Plain English
This study investigated how well a drug called Cerebrolysin works when given alongside standard stroke treatment (reperfusion therapy) in patients at different risks for complications. Out of 238 stroke patients monitored, those with moderate to high risk for bleeding (measured by a scoring system) showed significant improvement: the rate of symptomatic bleeding dropped from 21.1% in high-risk patients to just 4.3% in low-risk patients. This matters because it suggests that Cerebrolysin can help protect the brain and improve recovery for specific stroke patients during critical treatment stages. Who this helps: This helps stroke patients at moderate to high risk of complications.

Plain English
The COMPASS study looked at how a combination of rivaroxaban (2.5 mg twice a day) and acetylsalicylic acid (100 mg per day) can help prevent repeated non-coronary ischemic strokes. The findings showed that this combination is effective and safe for patients. This matters because it offers a new treatment option that can help reduce the risk of future strokes in certain patients. Who this helps: Patients at risk of recurrent non-coronary ischemic strokes.

Plain English
This study looked at the effects of a drug called dimephosphon on patients recovering from a type of stroke known as ischemic stroke in the carotid system. Researchers found that patients who received dimephosphon showed a 60% improvement in stroke severity scores compared to only 33% improvement in the group that did not receive the drug. By the 10th day of treatment, 83% of the treated patients had little to no disability, while only 60% of the comparison group reached that level. Who this helps: This benefits stroke patients during their early recovery phase.

Plain English
Researchers explored how COVID-19 affects the brain, finding that many patients experience lasting neurological symptoms that can persist for many months, leading to a new term called "Post-COVID-19 Condition." The Advisory Board of neurologists recommended a unified treatment approach for managing these complications, emphasizing the need for a special program to monitor patients post-COVID-19, which includes assessing cognitive functions to catch any neurodegenerative issues early. This is vital as it ensures patients receive appropriate care to address these long-term effects of the virus. Who this helps: Patients recovering from COVID-19 with neurological symptoms.

Plain English
This study looked at how effective the anxiolytic drug Tenoten is for treating anxiety in adults with specific mental health conditions, including somatoform dysfunction, reaction to severe stress, and adjustment disorders. After 12 weeks, patients taking Tenoten experienced a significant drop in anxiety scores, with those taking 8 tablets a day decreasing from an average of 18.38 to 6.40 on the Hamilton Anxiety Rating Scale. There were some side effects reported, but they were similar between those taking Tenoten and those on a placebo, indicating Tenoten is a safer and more effective option. Who this helps: This benefits adults suffering from anxiety related to specific mental health disorders.

Plain English
This study looked at how well repeated Botox injections help patients in Russia with muscle stiffness in their arms over two years. The research found that 85% of patients received the AboBoNT-A (Dysport) injection, showing notable improvement with a mean score of 51.1 on goal achievement, which is higher than the overall study group's score of 49.5. This matters because it demonstrates that personalized treatment goals and effective management can significantly enhance quality of life for these patients. Who this helps: Patients with upper limb spasticity.

Plain English
Doctors studied how to better rehabilitate stroke patients during the COVID-19 pandemic. They found that combining the care for stroke and COVID-19 requires new strategies to help patients recover effectively. This is important because stroke is a significant disability, and proper rehabilitation can greatly improve patients' quality of life. Who this helps: This helps stroke patients and their healthcare providers.

Plain English
This study looked at how a new treatment called "thresholdless" low-frequency transcranial magnetic stimulation could help patients recovering from an ischemic stroke. Researchers tested 93 patients and found that those who received this stimulation showed improvements: their mobility increased by 42.1%, functional independence improved by 38.1%, and muscle strength increased by 50% compared to those who only received standard care. This matters because it means that using this treatment could lead to faster recovery and better quality of life for people who have suffered a stroke. Who this helps: Stroke patients in their recovery process.

Plain English
This study looked at brain blood flow data to predict a condition called hemorrhagic transformation (HT) in patients who have had an acute ischemic stroke, specifically those affected in the middle part of the brain. Researchers analyzed data from 71 patients and found that in the area of the brain affected by the stroke (called the infarct core), a specific measurement known as permeability surface-area product (PS) could predict HT with an odds ratio of 8, meaning that higher PS was linked to a greater likelihood of HT occurring. This finding is significant because it offers a reliable way to identify which stroke patients are at greater risk for complications, allowing for better monitoring and treatment strategies. Who this helps: This helps doctors and patients by improving risk assessment and management after a stroke.

Plain English
This study looked at how blood clots behave in patients who have had an ischemic stroke compared to healthy individuals. Researchers found that blood clots from stroke patients contracted less than those from healthy people. Specifically, stroke patients had weaker clot reduction, which was linked to lower platelet counts and changes in blood composition that may affect how well clots function. This finding is important as it suggests that the way clots shrink could influence the severity and outcomes of a stroke. Who this helps: This helps patients who have had a stroke and doctors treating them.

Plain English
This study looked at how well botulinum toxin therapy helps people with muscle stiffness (spasticity) after having a stroke. Researchers tested 39 patients over nine months and found that those receiving the therapy early, within one to three months post-stroke, showed significant improvements in their ability to move their arms and walk, as well as a reduction in muscle weakness. These findings are important because they highlight that starting this treatment early can lead to better recovery outcomes for stroke survivors. Who this helps: This helps stroke patients who experience spasticity.

Plain English
This study looked at how effective and safe a drug called mexidol is for patients recovering from a type of stroke known as hemispheric ischemic stroke. Involving 151 patients, results showed that those receiving mexidol had better recovery scores than those getting a placebo: specifically, their scores on a disability scale improved significantly, and more patients showed no movement problems at the end of treatment. This matters because it shows that mexidol can help stroke patients recover more effectively, especially those with diabetes. Who this helps: This benefits stroke patients and their doctors by providing a new treatment option to improve recovery.

Plain English
Researchers developed a new tool called the hemorrhagic transformation index (HTI) to predict the likelihood of bleeding complications in patients who suffer a type of stroke known as middle cerebral artery (MCA) stroke within 14 days of the event. They studied data from 783 patients and found that the HTI can accurately assess risk, with scores ranging from 0 to 8 correlating with bleeding risk levels from just 2.7% (for a score of 0) to 98.3% (for a score of 8). This tool is significant because it helps guide treatment decisions, especially regarding when to resume blood-thinning medications after a stroke. Who this helps: This helps doctors and patients by improving management after a stroke.

Plain English
This study looked at how blood clots behave in patients experiencing an ischemic stroke, which occurs when blood flow to the brain is blocked. Researchers found that the blood clots in 85 stroke patients contracted much less effectively than those in healthy individuals, with notable changes in several blood components. This matters because understanding these changes can help explain why strokes can be more severe and may lead to new ways to treat or manage them. Who this helps: This helps patients who have had a stroke and their doctors.

Plain English
This study looked at how brain scans can help doctors understand the severity of a stroke and predict outcomes for patients. It focused on specific brain areas and blood vessels, identifying important factors (called the four Ps) that indicate the risk of severe damage or bleeding in the brain. The findings highlight that quick and detailed brain imaging can guide treatment decisions and improve patient care during a stroke. Who this helps: This helps doctors and healthcare providers treating stroke patients.

Plain English
This study looked at how well Botox treatment worked for 60 Russian patients with a condition called idiopathic cervical dystonia. The results showed that 88.3% of patients experienced at least a 25% improvement in their symptoms, 81.6% of patients and 81.7% of doctors reported significant improvements in treatment effectiveness, and the treatment was well tolerated by 98.3% of patients, with no severe side effects. This information is important because it provides strong evidence that Botox can be an effective and safe option for patients with this condition. Who this helps: This helps patients with idiopathic cervical dystonia and their treating doctors.

Plain English
This study looked at how effective Botulinum toxin type A (BoNT-A) injections are for helping people with muscle stiffness in their arms after a stroke. Out of 41 patients in Russia, nearly 88% achieved improvement in their treatment goals, with complete success in improving passive function and 95% achieving better movement range. This is important because it shows that BoNT-A can significantly enhance the daily lives of stroke survivors by reducing muscle stiffness and improving movement. Who this helps: This benefits stroke patients dealing with upper-limb spasticity.

Plain English
This study looked at how advanced brain imaging techniques can help predict the outcomes for patients who have had an acute ischemic stroke. The researchers found that these imaging methods can quickly show the extent of brain damage and other important factors, allowing doctors to better understand how well patients might recover. This is important because it helps tailor treatment plans to improve patient outcomes. Who this helps: Patients who have suffered a stroke and their doctors.

Plain English
This study looked at advanced brain imaging techniques used for patients experiencing a stroke. It found that these modern imaging methods can reveal critical information about the brain's condition, including the health of the brain tissue, blood vessels, and other key areas, which helps determine the severity of the stroke. Understanding these details is important for improving treatment decisions and patient outcomes. Who this helps: Patients suffering from acute ischemic stroke and their healthcare providers.

Plain English
This study looked at how a new system of medical care for stroke patients was set up in the Tatarstan Republic between 2008 and 2013. The researchers found that this multilevel care system improved outcomes for these patients. Specifically, the number of patients receiving timely and effective treatment increased significantly. Who this helps: This benefits stroke patients and their families in Tatarstan.

Plain English
This study looked at how different doses of botulinum toxin type A (BTA) can help with arm stiffness after a stroke. Researchers tested 68 patients in the early stages of recovery, finding that using a half dose significantly improved movement and prevented severe stiffness and painful shoulder issues. These findings are important because they suggest that lower doses can be effective, which may improve recovery and comfort for stroke patients. Who this helps: This helps stroke patients who experience arm spasticity and their healthcare providers.

Plain English
This study looked at how well tizanidine works when used alongside botulotoxin A to treat arm spasticity in stroke patients. Out of 44 patients, those who received both tizanidine and botulotoxin A showed significant improvements, including a decrease in muscle tightness and better muscle strength. This is important because it can help many stroke survivors regain more control over their arm movements and reduce discomfort. Who this helps: Patients recovering from strokes with arm spasticity.

Plain English
This study looked at how a new, multi-level system of medical care improved treatment for stroke patients in the Tatarstan Republic between 2008 and 2012. Researchers found that the number of stroke cases decreased, treatment became more effective, and fewer patients died from strokes. Additionally, more patients were able to live independently after treatment, indicating overall better care. Who this helps: This benefits stroke patients and their families.

Plain English
This study looked at how well adepress (paroxetine) works to treat depression in 39 patients recovering from ischemic strokes and those with chronic brain conditions. Researchers found that patients with faster ion transport in their cell membranes experienced more severe depression, but they also responded better to the medication. This means that measuring the speed of ion transport could help doctors identify patients who are at higher risk for depression and predict how effective the treatment will be. Who this helps: This helps patients recovering from strokes and chronic brain ischemia, as well as their doctors.

Plain English
Researchers studied 173 patients with brain damage from restricted blood flow who experienced different types of seizures. They found that 51.5% of seizures occurred after a stroke, while 48.5% were linked to chronic brain ischemia. Focal seizures were most common in patients with damage to the right side of the brain, and the areas of ischemia often did not match where the seizure activity was detected, especially in the left hemisphere. This research highlights how brain damage can affect seizure patterns, which is important for improving treatment strategies. Who this helps: This helps patients with vascular epilepsy and their doctors in managing seizures more effectively.

Plain English
This study looked at the effects of a drug called amantadine sulfate on stroke recovery in both rats and humans. In experiments with rats, the drug increased a protective protein called Hsp70, which helps the brain recover from damage caused by lack of blood flow. In a clinical trial with 40 stroke patients, those who received amantadine showed faster improvement in alertness and neurological function compared to those who received magnesium sulfate, especially within the first day after treatment. Who this helps: This benefits stroke patients by providing a potentially faster recovery option.

Plain English
This study examined new advanced treatments for patients experiencing ischemic stroke at a medical center in Kasan. The researchers found that using targeted treatments like intravenous thrombolysis and balloon angioplasty significantly improved patient outcomes when done quickly and tailored to individual needs. Specifically, these methods lead to better recovery for those suffering from acute strokes. Who this helps: This helps stroke patients receive faster and more effective treatment options.

Plain English
This research studied the nerve and muscle activity in 20 rats that naturally have high blood pressure (spontaneously hypertensive rats) compared to 22 regular Wistar rats. The results showed that the rats with high blood pressure exhibited signs of a condition called tetany, which indicates an unusual level of muscle excitability. Understanding these changes is important because it could help identify nerve and muscle problems in patients with high blood pressure. Who this helps: Patients with high blood pressure.

Plain English
This study looked at brain imaging results from 593 healthy children and teenagers aged 2 to 20 to understand how these results change as they grow. Researchers identified normal measurements for different ages that can help doctors spot brain issues in the future. They found specific trends, like how distances measured in the brain change as kids get older, which is important for accurate diagnoses. Who this helps: This information helps doctors and medical professionals diagnose brain conditions in children more effectively.

Plain English
This study looked at 403 children and teenagers aged 8 to 20 who have various vegetative disorders, which affect their brain function. The researchers found that nearly half (49%) of these patients had a significant enlargement of a specific brain area called the third ventricle. This finding shows that echoencephalography is an important tool for diagnosing brain issues in young people with these disorders. Who this helps: This helps doctors and healthcare providers understand and diagnose brain problems in children and adolescents more effectively.